Skip to content
CancerIndex

Publication

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.

Authors not recorded

Proc Natl Acad Sci U S A2012PMID 23236167PMC3535655stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23236167
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
EZH2 Y646F2
(oncogenic)Diffuse Large B-Cell LymphomaCURATED_BROADEROncogenicDSupports Oncogenicity3submitted
EID11012

A selective EZH2 inhibitor (EI1) and siRNA were used to inhibit EZH2 Y641F mutation in DLBCL mutated cell line (WSU-DLCL2). Two independent siRNAs knocked down EZH2 mRNA by almost 80% and inhibited c… (full text at CIViC)

PMID 23236167 · Qi et al., 2012 · Open in CIViC

civic
(functional)—UNRESOLVEDFunctionalDSupports Gain Of Function2submitted
EID11010

DLBCL cell line carrying the EZH2 Y641F mutation (WSU-DLCL2 ) was used to study the effect of a selective EZH2 inhibitor (EI1) on these cells. Immunoblot assay showed an increase in baseline H3K27me3 … (full text at CIViC)

PMID 23236167 · Qi et al., 2012 · Open in CIViC

civic
EZH2 Y646N2
(oncogenic)Diffuse Large B-Cell LymphomaCURATED_BROADEROncogenicDSupports Oncogenicity4accepted
EID11013

A selective EZH2 inhibitor (EI1) was used to target the EZH2 Y641N mutation in DLBCL cell lines. EI1 treatment significantly inhibited proliferation in EZH2-mutated cells compared to lymphoma cells wi… (full text at CIViC)

PMID 23236167 · Qi et al., 2012 · Open in CIViC

civic
(functional)—UNRESOLVEDFunctionalDSupports Gain Of Function3accepted
EID11011

DLBCL cell lines carrying the EZH2 Y641N mutation (SU-DHL6 and Karpas422) were used to study the effect of EI1, a selective EZH2 inhibitor that functions by competing with the methyl group donor S-Ade… (full text at CIViC)

PMID 23236167 · Qi et al., 2012 · Open in CIViC

civic